Profitable pharma GxP compliance group, 300+ clients

Exit readiness

7 of 100

Exit readiness. How much of the paperwork buyers ask for in diligence is already in this listing’s data room.

Illustrative image. This photo may be AI-generated and may not show the actual business or its assets.

Profitable pharma GxP compliance group, 300+ clients

Health CareDubai, Dubai, United Arab Emirates

Deal information

Est. 2004Health Care
Asking price
AED 13.4M
Revenue
AED 3.9M
Profit
AED 1.3M
Price / annual profit
10.1x

This ratio uses the whole business asking price and the latest closed financial year’s net profit. It can differ from the seller’s SDE or EBITDA valuation multiple.

Sign up free to contact the seller

Description

A pharmaceutical regulatory and compliance services group providing GxP auditing, EU GMP and OECD GLP certification support, regulatory affairs and life-cycle management (marketing-authorisation holding, pharmacovigilance) and technology transfer services to generic-drug, API and biosimilar developers, manufacturers and marketers. Revenue mixes fixed-price turnkey projects, repeat three-yearly compliance cycles and recurring MA-holding/pharmacovigilance mandates, supplemented by sales from a digital library of several hundred ready-to-use audit reports. The group employs 46 staff across Europe, Asia and MENA, serves 300+ clients in 40+ countries, earns roughly half of revenue from repeat customers, and its largest client represented 6.9% of FY2025 revenue.

Reason for sale

The founder is divesting the services business to focus full-time on the affiliated products business, carved out into a separate entity in January 2026, which he will continue to lead. Management, clients and operating structure remain in place, with a handover period agreed.

Products & services

Single-window GxP compliance, regulatory and technology services for generic pharma, APIs and biosimilars. Five lines: GxP audits (150–200 per year, plus a Digital Audit Library of 500+ ready-to-purchase reports); EU GMP and OECD GLP certification turnkey projects (65+ facilities certified, 20+ ongoing); regulatory affairs and market access (CTD dossiers, MA holding, pharmacovigilance, batch release); technology (product development, tech transfer, bioequivalence, 100+ technologies available); facility design, QMS remediation and sourcing.

Customers & market

300+ clients across 40+ countries, from large pharma to SMEs. Revenue by region in FY2025: China 32%, Europe & CIS 26%, India 23%, rest of Asia 16%, MEA 3%. Low concentration — the largest client is 6.9% of revenue and the top five together 28.8%. Around 50% of 2025 revenue came from repeat customers, with 25–30 key accounts, some served every year since 2006. GMP audits must be renewed every three years, which builds a natural recurring cycle.

Operations & team

46 employees, rising to 55 by 2029. Asset-light model with operations teams based in India (44%) and China (26%), keeping the cost base low, and client-facing offices in Malta, Germany and Dubai. Staff turnover below 12% since inception. Second-line management is fully in place: a COO with 33 years of experience leads all operations, and each head of department brings at least 15 years in their specialism. Business development, operations and management already run largely independently of the Founder, who will stay on for a handover period.

Growth opportunities

Order book of EUR 9.0+ million in signed contracts, 53% still to be invoiced and revenue visibility through to Q2 2029, plus EUR 2.5+ million in projects under negotiation. 50+ GMP audits are already scheduled for 2026. Three new service lines are in the pipeline: biosimilars consulting (two monoclonal antibodies with patents expiring 2029–30), CRO design and commissioning in greenfield markets, and a dedicated Brazil/ANVISA desk. The carved-out products business remains a captive client under a master service agreement, contributing an estimated EUR 624k in 2026 and rising to EUR 1.5 million by 2029. EBITDA margin is projected at 40%+ from 2027 onwards.

Revenue and earnings by year

What the seller filed for each closed financial year, plus a trend for next year worked out from those years. The full accounts and the line-by-line detail sit behind an enquiry.

RevenueEBITDAPart yearTrend
Financial yearRevenueEBITDA
FY2023AED 2,337,000AED 549,000
FY2024AED 2,915,000AED 1,218,000
FY2025AED 3,867,000AED 1,478,000
FY2026Part year, up to November 2026AED 4,338,000AED 1,682,000
FY2026 (trend)AED 4,569,667AED 2,010,667

FY2026 is a part year: it covers only the months up to November 2026. It is not a full year, so it should not be compared with the full years, and it is not used in the trend.

SellAnyBiz works this trend out from the 3 closed financial years above: a straight-line (least-squares) trend through them, extended one year, the same way for every listing. It is not a figure the seller gave.

Valuation

The seller's own method comes first. The other tabs read the same figures a different way — only methods the seller's figures can actually answer are shown.

EBITDA multiple

Seller's method

AED 13,440,000

EBITDA AED 1.7M × 8.00

From valuation to the asking price

Whole business value before adjustment
AED 13,440,000
Whole business asking price
AED 13,440,000

The valuation covers the whole business. The asking price includes the seller’s premium or discount. A stake offer uses its proportional share of the asking price.

Recommended businesses for sale

Similar deals buyers are exploring right now.

View all
UAE Marine Supply & Services Group — 13+ Years
Verified
Exit readiness score 6 out of 100

2M

AED · Asking price

Maintenance

UAE Marine Supply & Services Group — 13+ Years

Dubai, United Arab Emirates

Revenue
AED 8.5M
Profit
AED 287K
Whole price / annual profit
7.0x
View details

Asking price

AED 13.4M

Sign up free to contact the seller